BROWN RUDNICK LLP for APOTEX CORPORATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 18, 2012 | $40,000 | Replaced |
| 2nd Quarter - Amendment (No Activity) | Aug 25, 2017 | $50,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues relating to REMS and Orange Book patent listing S. 1882 - Fair GeneRxics Act H.R. 4332 - Generic Drug Appliction Review Fairness Act of 2012 H.R. 5651 & S. 2516 & S. 3187 - FDA Safety and Innovation Act
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct and/or indirect ownership interest in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | — |
| RUSSELL CONWELL RING | Intern, Rep. Paris (84); LA, Rep. Paris (85-86) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.